StemGenex
StemGenex is a private San Diego-based stem cell therapy clinic founded in 2007 that provides patient access to regenerative cell-based treatments for individuals with inflammatory and degenerative illnesses, operating with 11-50 employees.
- Company typePrivate
- Founded2007
- HeadquartersSan Diego, United States
- Headcount11–50
- GTM typeB2C
- OfferingServices
What StemGenex does
StemGenex is a private for-profit stem cell therapy provider headquartered in San Diego, California, founded in 2007. The company describes its mission as providing patient access to stem cell therapy for individuals suffering from inflammatory and degenerative illnesses. It operates as a clinical services organization with 11-50 employees, indicating a small-scale practice rather than a multi-site healthcare system. Rita Alexander serves as Founder and Chief Administrative Officer, consistent with a founder-led operating model that has been in place since inception.
The company's core offering centers on administering stem cell-based treatments, though specific treatment protocols, cell types processed, regulatory pathways (e.g., autologous vs. allogeneic, FDA 361 HCT/P vs. IND-regulated biologics), and clinical indications are not disclosed in the available data. No proprietary technology platforms, patents, or scientific publications are referenced, and the technology footprint appears limited to standard clinical operations rather than a technology-driven business model.
Business model details are not disclosed in available data, but the positioning as a direct-access stem cell therapy provider implies patient-pay clinical services revenue, typical of cash-pay regenerative medicine clinics in the U.S. market. No pricing structure, patient volume figures, payer relationships, partnerships, or revenue disclosures are available. The input corpus is dominated by unrelated third-party content (a Dutch online casino review website), which provides no material company information.
StemGenex firmographics
Firmographics- Name
- StemGenex
- Legal name
- Not available - no legal name found in source content for StemGenex
- Website
- https://stemgenex.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- StemGenex is a private San Diego-based stem cell therapy clinic founded in 2007 that provides patient access to regenerative cell-based treatments for individuals with inflammatory and degenerative illnesses, operating with 11-50 employees.
- Ownership category
- akta.pro rank
StemGenex industry classification
Industry- Product category
- Regenerative Medicine
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Health Services (8000)
- akta.pro primary industry
- Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)
- akta.pro secondary industries
- Stem Cell–Based Regenerative Therapies (HLAAAGAA), Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics) (HLAAAGAL), Cell Therapy Developers (Autologous) (HLAAABAA)
Keywords
Where StemGenex is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Markets served
StemGenex business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D
StemGenex product offering
Product offeringCore offering
StemGenex is dedicated to providing access to adult stem cell therapy for individuals suffering with inflammatory and degenerative illnesses. The company delivers autologous (patient-derived) stem cell treatments at its San Diego clinical site, processing and re-administering patients' own stem cells as a regenerative therapy.
Differentiator
Problem solved
Functional benefit
Products and services
- Adult Stem Cell Therapy Stem cell therapy service in which adult stem cells (derived from the patient's own tissue) are processed and re-administered to treat inflammatory and degenerative illnesses. The service is offered to individual patients at StemGenex's San Diego clinical site.
Companies that use StemGenex
Customer profileIdeal customer profiles1 record
StemGenex technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
StemGenex partnerships and signals
Strategic signalRecent moves1 record
Expansion highlights1 record
StemGenex competitors and assessment
Company assessmentDirect peers
- NSI Stem Cell: NSI Stem Cell operates a national US clinic network providing autologous stem cell therapies for musculoskeletal and systemic conditions. Highly comparable to StemGenex in clinic model, indications served, and direct-to-patient marketing approach.
- Celltex Therapeutics: Celltex Therapeutics is a Houston-based stem cell therapy company offering autologous mesenchymal stem cell banking and treatments. It overlaps with StemGenex on cell source (autologous MSC), regenerative medicine indications, and US clinic-based delivery model.
- BioXcellerator: BioXcellerator operates stem cell clinics treating inflammatory, autoimmune, and degenerative conditions using bone marrow and adipose-derived stem cells. Comparable to StemGenex in therapeutic focus, autologous sourcing, and premium cash-pay clinic delivery model.
- Regenexx: Regenexx is a US-based network of clinics offering autologous stem cell and platelet-rich plasma treatments for orthopedic and inflammatory conditions. It is the most directly comparable peer to StemGenex in terms of service model, target indications, and direct-to-consumer cash-pay approach.
- The Lung Institute: The Lung Institute is a US-based regenerative medicine clinic specializing in stem cell therapy for chronic pulmonary and inflammatory conditions. Comparable to StemGenex in clinic-based, direct-to-consumer stem cell service delivery.
- GIOSTAR: GIOSTAR is a regenerative medicine clinic group offering stem cell therapies for inflammatory and degenerative diseases with locations in the US and internationally. It is comparable to StemGenex across indication focus, autologous stem cell delivery, and consumer-targeted positioning.
Broad incumbents
- AgeX Therapeutics: AgeX Therapeutics is a US-based biotechnology company focused on regenerative medicine and cellular therapies for age-related degenerative diseases. It is a broader incumbent operating earlier in the value chain (R&D rather than clinic delivery), but addresses the same underlying indication categories as StemGenex.
- Mesoblast: Mesoblast is an Australian-listed clinical-stage biotechnology company developing allogeneic cellular medicines for inflammatory and degenerative diseases. It is a broader incumbent addressing overlapping indications (e.g., degenerative disc disease, heart failure) but delivers via pharmaceutical rather than clinic channels.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
StemGenex social profiles
Digital presenceStemGenex financial estimates
Financial estimateRevenue estimate
Valuation estimate
StemGenex leadership team
Management profileNumber of profiles
Profiles1 record
StemGenex funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
StemGenex M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about StemGenex
What does StemGenex do?
StemGenex is dedicated to providing access to adult stem cell therapy for individuals suffering with inflammatory and degenerative illnesses. The company delivers autologous (patient-derived) stem cell treatments at its San Diego clinical site, processing and re-administering patients' own stem cells as a regenerative therapy.
When was StemGenex founded?
StemGenex was founded in 2007. It employs 11 to 50 people.
Where is StemGenex based?
StemGenex is headquartered in San Diego, United States, in the North America region.
Who are StemGenex's main competitors?
Direct peers on record are NSI Stem Cell, Celltex Therapeutics, BioXcellerator, Regenexx, The Lung Institute and GIOSTAR. Broad incumbents are AgeX Therapeutics and Mesoblast.
Does StemGenex have an API?
No public API is recorded for StemGenex.
What industry is StemGenex in?
StemGenex's product category is Regenerative Medicine. Its primary akta.pro industry code is HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived), with a secondary code of HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 541714 and its SIC code is 8000.